Jump to content

Recommended Posts

Posted
16 hours ago, Wally Fairway said:

Was this a "Kamala Harris AI report" about GERN's institutional ownership?  

 

"Geron has 71% of its shares owned institutionally, so that means institutions own a great majority of it.  So what does that mean?  Institutions own 71% of the shares!"  

 

not really a write up, but it is good that institutions are betting on it.  

  • Hook 'Em 2
Posted

I sold out all my Palantir around last month at $33 because I thought it was overpriced (cost basis 16 or something)
 

Been on a straight line the last 30 days, at $43 now ☠️

Posted
5 minutes ago, Trey3216 said:

IBRX goes up to $4, IBRX comes back to $3.25.  

 

WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

If it helps with perspective, it was above $9 in April!

Posted
On 10/10/2024 at 2:18 PM, 52-80 said:

I sold out all my Palantir around last month at $33 because I thought it was overpriced (cost basis 16 or something)
 

Been on a straight line the last 30 days, at $43 now ☠️

Pre or post announcement to S&P 500?

Posted
4 hours ago, T’Boo Ted Marshall said:

DRUG with a 750% move at time of posting.  

damn...people were getting in at sub $3 today in mass...

closed at 38.49 and was trading after hours above $54 before coming back down to $37

 

image.png.0c6f00be7e280f2bced5199fc656ee2d.png

  • Hook 'Em 1
  • Like 2
  • Drool 3
Posted
6 hours ago, T’Boo Ted Marshall said:

It started at .93 yesterday.
How the hell does that happen?

https://finance.yahoo.com/news/bright-minds-unaware-material-changes-010900911.html

Some dude released it as a hot "buy" on a penny stock discord server, people started buying it, and due to the low float (4.5M)  it takes off, causes more people to buy it,etc.... just another pump and dump, although more successful than most. Probably be back down to $1-2 before long. 

  • Like 1
Posted
11 hours ago, B00M said:

Should we sell UUUU, keep buying regardless, or wait for it to come back? 

It's a stock with a lot of volatility. They seem to have transitioned from a pure uranium play to being more rare earth's with a chunk of uranium still. I got out when they made the acquisition of the African mining company a few months ago and am not looking back. 

Posted

Username oddly specific!  I am watching UUUU but not in it right now.  Just wallowing in my miserable IBRX waiting room.  One of these days we’ll get some Anktiva sales preview and hopefully start moving.

  • Haha 6
  • Fuck Around and Find Out 1
Posted
On 10/17/2024 at 7:57 AM, Hefeweizen said:

Username oddly specific!  I am watching UUUU but not in it right now.  Just wallowing in my miserable IBRX waiting room.  One of these days we’ll get some Anktiva sales preview and hopefully start moving.

Revenue from Anktiva sales for the treatment of bladder cancer should begin showing up in each of the next several quarters and the application to the EU and UK for Anktiva approval should be completed before the end of the year.  This would expand IBRX’s bladder cancer therapy to 30 countries making it available as early as mid-2025.  The NSCLC trial would be huge if it shows similar results to the quilt trial. That’s the largest cancer market in the world.

  • Hook 'Em 1
Posted
1 hour ago, Trey3216 said:

Thanks for not tagging him.  We don't need that ingrate screwing up this thread.  

"Hey guys twitter told me that Amazon is the stonk to buy this year" 

  • Haha 2
Posted

“EF Hutton analyst Jason Kolbert initiated coverage of ImmunityBio stock with a Buy rating and a $30 price target on Wednesday. That implies a startling 767% upside to its current share price of $3.46.

ImmunityBio is a San Diego, Calif.-based late-stage clinical biotech poised to revolutionize cancer immunotherapy, according to Kolbert.

The company’s lead product Anktiva works by activating the body’s natural immune system to eliminate tumor cells and provide long-term immune memory against cancer. It was approved by the Food and Drug Administration in April this year for adult patients with a cancer unresponsive to the most common intravesical immunotherapy (BCG), non-muscle invasive bladder cancer.

 

Anktiva’s ability to convert cold tumors into hot ones—making them more responsive to immune attack—is particularly effective as cold tumors typically evade detection, Kolbert noted. This can potentially improve outcomes in various cancers, including those traditionally treated with checkpoint inhibitors, such as melanoma, lung, ovarian, and colorectal cancers, by making them more vulnerable to an immune system attack, he added.

The small-cap company has a market value of $2.8 billion, and has yet to report a quarterly profit since its listing on Nasdaq in March 2021, which isn’t uncommon for start-up biotechs.

The stock rose 8.7% to $3.76 Thursday. At Wednesday’s close, the stock was down 31% for the year”.

^^^^^^^^^^^^^^^^^^^^^

An article in today’s Barron’s.  IBRX +.68 to $4.14.  Today’s price will be a distant memory when the stock’s at $100/share.  

  • Hook 'Em 1
Posted

IBRX Adding news from this morning...

  • Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors

  • First natural killer cell-based cellular therapy study conducted in the continent of Africa

  • Complete enrollment currently expected in Q1 2025

CULVER CITY, Calif., October 24, 2024--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy targeting CD-19 in the treatment of non-Hodgkin’s lymphoma (NHL).

  • Hook 'Em 2
  • Like 1
Posted

I’m no Harrison but I’ve accumulated enough shares to make a run a lot of fun.  I was very close to adding a couple thousand more shares Monday and bought some GERN instead as it’s sitting under 4 still.   Let’s roll!

  • Like 1
Posted

Here's a blast from the past, one of the OG stonks on this thread. UAVS popped up on the best performing stocks today (up 50%), and I was actually surprised that they were still in business. After looking at their chart since the insanity of '21, it would appear things have been trending poorly. I still laugh at the thought that Amazon was gonna partner with these chucklefucks when Amazon had already invested in their own drone delivery business to the tune of like $30B. 

image.png.af748ca5d4ef31e697213637dd6b2dfc.png

 

This quote from the new CEO after their most recent 50:1 split a couple of days ago is fantastic:

Quote

In conclusion, through a combination of our key initiatives, growing demand, and demonstrated progress in our newest market, I believe AgEagle is on the correct path to increase long-term shareholder value. We appreciate your continued support.

Keep on stonkin', sir.

  • Haha 2
Posted
Just now, Harrison Stafford said:

IBRX +$1.61 to $5.82.  Still a third of the float sold short.

nearly 40% on 8x the 10 day average volume (which includes 6x average volume yesterday).   That is a stronk move 

  • Hook 'Em 3

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.



×
×
  • Create New...